Your browser is no longer supported. Please, upgrade your browser.
RGLS Regulus Therapeutics Inc. daily Stock Chart
Regulus Therapeutics Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own0.90% Shs Outstand24.06M Perf Week1.27%
Market Cap20.01M Forward P/E- EPS next Y-0.84 Insider Trans-4.00% Shs Float16.45M Perf Month-14.59%
Income-21.30M PEG- EPS next Q-0.11 Inst Own35.50% Short Float4.34% Perf Quarter13.84%
Sales0.06M P/S333.57 EPS this Y80.70% Inst Trans0.61% Short Ratio0.25 Perf Half Y-29.55%
Book/sh0.62 P/B1.15 EPS next Y-23.50% ROA-68.50% Target Price1.00 Perf Year16.51%
Cash/sh- P/C- EPS next 5Y39.60% ROE-215.30% 52W Range0.43 - 1.74 Perf YTD-20.06%
Dividend- P/FCF- EPS past 5Y41.30% ROI-48.10% 52W High-59.11% Beta2.17
Dividend %- Quick Ratio1.70 Sales past 5Y-2.30% Gross Margin- 52W Low65.47% ATR0.09
Employees21 Current Ratio1.70 Sales Q/Q-99.90% Oper. Margin- RSI (14)41.72 Volatility8.53% 12.52%
OptionableYes Debt/Eq0.98 EPS Q/Q21.40% Profit Margin- Rel Volume0.33 Prev Close0.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.81M Price0.71
Recom2.70 SMA20-11.57% SMA50-12.49% SMA200-5.47% Volume917,764 Change-1.86%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Aug-06-20 12:30PM  
Aug-03-20 08:07AM  
Jul-29-20 08:07AM  
Jul-22-20 08:07AM  
Jun-12-20 08:01AM  
May-14-20 04:07PM  
May-07-20 12:30PM  
Mar-12-20 04:37PM  
Mar-09-20 12:30PM  
Feb-13-20 04:30PM  
Jan-21-20 07:47AM  
Dec-22-19 07:44PM  
Dec-16-19 08:00AM  
Nov-18-19 08:07AM  
Nov-15-19 01:37PM  
Nov-12-19 05:55PM  
Nov-07-19 10:30AM  
Oct-16-19 04:15PM  
Sep-20-19 01:30PM  
Sep-12-19 08:00AM  
Sep-03-19 04:10PM  
Aug-29-19 04:10PM  
Aug-08-19 07:20PM  
Aug-06-19 02:50PM  
Aug-01-19 10:33AM  
Jul-30-19 08:00AM  
Jul-29-19 11:33AM  
Jul-23-19 06:30PM  
Jun-11-19 05:00AM  
May-10-19 05:39AM  
May-09-19 04:05PM  
May-07-19 04:05PM  
May-06-19 09:15AM  
May-02-19 10:32AM  
Apr-08-19 08:00AM  
Mar-28-19 09:45AM  
Mar-18-19 08:53AM  
Mar-15-19 06:00PM  
Jan-07-19 08:00AM  
Jan-04-19 04:05PM  
Dec-20-18 09:56AM  
Nov-28-18 07:35AM  
Nov-19-18 08:00AM  
Nov-08-18 06:40PM  
Nov-06-18 07:30AM  
Oct-25-18 04:05PM  
Oct-23-18 11:30AM  
Oct-22-18 04:05PM  
Oct-18-18 04:05PM  
Oct-17-18 07:45AM  
Oct-04-18 08:05AM  
Oct-02-18 04:05PM  
Sep-27-18 04:05PM  
Sep-26-18 04:05PM  
Sep-19-18 02:22PM  
Aug-23-18 12:50PM  
Aug-09-18 06:10PM  
Jul-09-18 09:13AM  
Jul-05-18 05:00PM  
Jul-03-18 12:38PM  
Jun-12-18 07:45AM  
May-17-18 07:40AM  
May-10-18 11:46PM  
May-03-18 04:15PM  
May-01-18 08:30AM  
Apr-17-18 04:10PM  
Mar-20-18 04:15PM  
Mar-09-18 12:11AM  
Mar-07-18 04:31PM  
Mar-05-18 07:01PM  
Mar-02-18 08:00AM  
Feb-28-18 04:15PM  
Feb-22-18 02:23AM  
Feb-08-18 04:15PM  
Jan-05-18 08:00AM  
Dec-19-17 08:30AM  
Nov-13-17 06:10PM  
Nov-07-17 06:36PM  
Oct-31-17 04:15PM  
Oct-03-17 08:53AM  
Aug-30-17 04:15PM  
Aug-25-17 08:35AM  
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PPresident and CEOMay 15Sale0.634,4262,774226,333May 18 04:28 PM
Aker Christopher RaySr. VP & General CounselMay 15Sale0.6390957027,510May 18 04:27 PM
Hagan Joseph PPresident and CEOFeb 18Sale0.834,3243,591230,759Feb 19 06:09 PM
Aker Christopher RaySr. VP & General CounselFeb 18Sale0.8388873728,419Feb 19 06:08 PM
Aker Christopher RaySr. VP & General CounselJan 02Sale0.972,2392,16429,307Jan 03 04:06 PM
Hagan Joseph PPresident and CEOJan 02Sale0.978,3458,067235,083Jan 03 04:07 PM
Aker Christopher RaySr. VP & General CounselNov 14Sale0.6483353331,546Nov 15 05:37 PM
Hagan Joseph PPresident and CEONov 14Sale0.645,8383,736243,428Nov 15 05:36 PM
Aker Christopher RaySr. VP & General CounselOct 01Sale0.682,3461,60232,379Oct 02 06:50 PM
Hagan Joseph PPresident and CEOOct 01Sale0.688,7435,969249,266Oct 02 06:17 PM
Hagan Joseph PPresident and CEOAug 15Sale0.554,3752,409258,009Aug 16 04:17 PM
Aker Christopher RaySr. VP & General CounselAug 15Sale0.5589949534,725Aug 16 04:16 PM